Medidata dives into Japanese trials; China targets Indian scientists;

> Medidata ($MDSO) is lending its cloud-based technology to a Japanese pharma group, collaborating to calculate the cost of running clinical trials in the country. More

> Chinese research organizations are poaching Indian scientists in hopes of building up their local formulation expertise, according to The Economic Times. News

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.